Drug Combination Details
| General Information of the Combination (ID: C38026) | |||||
|---|---|---|---|---|---|
| Name | Artemisinin NP Info | + | Halofuginone Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Colon cancer
[ICD-11: 2B90]
|
Investigative | [1] | ||
|
Breast cancer
[ICD-11: 2C60]
|
Investigative | [1] | |||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | CDKN1A | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | CDKN1B | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | HCT 116 | CVCL_0291 | Colon carcinoma | Homo sapiens | ||
| SW480 | CVCL_0546 | Colon adenocarcinoma | Homo sapiens | |||
| SW620 | CVCL_0547 | Colon adenocarcinoma | Homo sapiens | |||
| MCF-7 | CVCL_0031 | Invasive breast carcinoma | Homo sapiens | |||
| A-375 | CVCL_0132 | Amelanotic melanoma | Homo sapiens | |||
| MGC-803 | CVCL_5334 | Gastric mucinous adenocarcinoma | Homo sapiens | |||
| Hep-G2 | CVCL_0027 | Hepatocellular carcinoma | Homo sapiens | |||
| Hep 3B2.1-7 | CVCL_0326 | Childhood hepatocellular carcinoma | Homo sapiens | |||
| In-vivo Model | HCT116 cells (5*106 cells per mouse) were suspended in PBS and inoculated subcutaneously into the left flank of each female BALB/c nude mice. | |||||
| Experimental
Result(s) |
Halofuginone and artemisinin synergistically arrest cancer cells at the G1/G0 phase by upregulating p21Cip1 and p27Kip1. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Halofuginone and artemisinin synergistically arrest cancer cells at the G1/G0 phase by upregulating p21Cip1 and p27Kip1. Oncotarget. 2016 Aug 2;7(31):50302-50314. | |||
